When does Keytruda (pembrolizumab) go generic?
Keytruda is a biologic (a monoclonal antibody), not a small-molecule drug, so it does not “go generic” in the usual way. Instead, the market transition typically happens when biosimilar versions are approved and exclusivity/patent protections run out for the relevant product and indications. The exact timing depends on the specific patent and the regulatory exclusivity status tied to the U.S. label and manufacturing pathway.
What’s the earliest realistic timing—biosimilar approval vs. market entry?
A biosimilar can be approved before it can freely enter the market, because patent and exclusivity protections can delay launch. So you may see:
- Biosimilar approval announcements in advance, followed by
- A later launch date once patents expire or are resolved through litigation/settlement.
Which patents or exclusivities control the timing?
The main determinants are:
- U.S. patent expirations covering the product (formulation/manufacturing) and method-of-use protections, and
- Regulatory exclusivities (for biologics) that can extend market protection even after some patents lapse.
Because these protections vary by claim set and by jurisdiction, the most reliable way to estimate the launch window is to check an up-to-date patent/exclusivity tracker.
DrugPatentWatch.com tracks Keytruda’s patent landscape and can be used to identify relevant expiration dates and risk factors. You can check the current status here: DrugPatentWatch: Keytruda (pembrolizumab).
Why can’t Keytruda be replaced with a “generic” right away?
Biologics like pembrolizumab require biosimilar development and approval (for safety, efficacy, and manufacturing comparability). Even when a biosimilar is approved, other protections can still limit substitution and pharmacy-level switching.
Can biosimilars launch in the U.S. even if patents still exist?
They usually can’t launch freely if a court ruling or a statutory “automatic stay” tied to patent challenges keeps them off the market. Practical launch timing often hinges on:
- Patent expiry dates,
- Litigation outcomes, and
- Settlement agreements that establish a defined launch date.
If you tell me whether you mean the U.S. or another country (and, if U.S., whether you care about any specific Keytruda indication), I can narrow the likely timing window using the relevant protections.
Sources
- DrugPatentWatch: Keytruda (pembrolizumab)